159 related articles for article (PubMed ID: 22152181)
21. [Further characterization between oral bisphosphonate dosing interval and patient preference--patient preference for daily, weekly and monthly bisphosphonate, based on results of 3,052 outpatients questionnaires].
Ijiri S
Nihon Rinsho; 2013 Dec; 71(12):2223-31. PubMed ID: 24437282
[TBL] [Abstract][Full Text] [Related]
22. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
23. The Diabetes Continuity of Care Scale: the development and initial evaluation of a questionnaire that measures continuity of care from the patient perspective.
Dolovich LR; Nair KM; Ciliska DK; Lee HN; Birch S; Gafni A; Hunt DL
Health Soc Care Community; 2004 Nov; 12(6):475-87. PubMed ID: 15717895
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
[TBL] [Abstract][Full Text] [Related]
25. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
Kendler D; Kung AW; Fuleihan Gel-H; González González JG; Gaines KA; Verbruggen N; Melton ME
Maturitas; 2004 Jul; 48(3):243-51. PubMed ID: 15207890
[TBL] [Abstract][Full Text] [Related]
26. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
Muratore M; Quarta L; Calcagnile F; Quarta E
Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
[TBL] [Abstract][Full Text] [Related]
27. Development of a multidimensional measure for recurrent abdominal pain in children: population-based studies in three settings.
Malaty HM; Abudayyeh S; O'Malley KJ; Wilsey MJ; Fraley K; Gilger MA; Hollier D; Graham DY; Rabeneck L
Pediatrics; 2005 Feb; 115(2):e210-5. PubMed ID: 15687428
[TBL] [Abstract][Full Text] [Related]
28. Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire).
Kimman ML; Rotteveel AH; Wijsenbeek M; Mostard R; Tak NC; van Jaarsveld X; Storm M; Wijnsma KL; Gelens M; van de Kar NCAJ; Wetzels J; Dirksen CD
Patient; 2017 Oct; 10(5):629-642. PubMed ID: 28357591
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q).
Ruiz MA; Pardo A; Rejas J; Soto J; Villasante F; Aranguren JL
Value Health; 2008; 11(5):913-26. PubMed ID: 18494753
[TBL] [Abstract][Full Text] [Related]
30. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
31. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
32. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
33. Measuring patient satisfaction with diabetes disease state management services in community pharmacy.
Krass I; Delaney C; Glaubitz S; Kanjanarach T
Res Social Adm Pharm; 2009 Mar; 5(1):31-9. PubMed ID: 19285287
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
35. Validation of the Chinese version of the satisfaction with the nursing home instrument.
Lee LY; Lee DT; Woo J; Wong EM
J Clin Nurs; 2006 Dec; 15(12):1574-82. PubMed ID: 17118080
[TBL] [Abstract][Full Text] [Related]
36. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
Lin T; Wang C; Cai XZ; Zhao X; Shi MM; Ying ZM; Yuan FZ; Guo C; Yan SG
Int J Clin Pract; 2012 Apr; 66(4):399-408. PubMed ID: 22313934
[TBL] [Abstract][Full Text] [Related]
37. [Denosumab--a new efficient osteoporosis therapy].
Rejnmark L; Vestergaard P; Mosekilde L
Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
[TBL] [Abstract][Full Text] [Related]
38. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
39. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
40. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
